Literature DB >> 436339

Peritoneal clearance and total body elimination of vancomycin during chronic intermittent peritoneal dialysis.

J C Ayus, J F Eneas, T G Tong, N L Benowitz, P Y Schoenfeld, K L Hadley, C E Becker, M H Humphreys.   

Abstract

Vancomycin is a useful antimicrobial agent in patients undergoing chronic hemodialysis treatment; its efficacy in chronic peritoneal dialysis (CPD) has not been established. Serum (VS) and peritoneal fluid (VPF) vancomycin concentrations were measured in two CPD patients with staphylococcal peritonitis. Half-life of VS agreed with the half-life of VPF in each patient, and the VS/VPF ratio was 1.27 in both patients. Distribution volumes were 37.2 and 58.7 l, values approximating total body water in these patients. VS and VPF persisted in the therapeutic range (greater than 5 microgram/ml) for more than 16 days. In one patient, mean peritoneal clearacne was 9.8 ml/min, and overall drug clearance averaged 2.3 ml/min; in the other patient, overall clearance was 2.1 ml/min. These results indicate that therapeutic vancomycin levels can be maintained for more than 16 days with a single 1 g intravenous dose in patients receiving intermittent CPD, as is the case for hemodialysis patients. Because of this, parenteral vancomycin is useful in the treatment of staphylococcal peritonitis in CPD patients.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 436339

Source DB:  PubMed          Journal:  Clin Nephrol        ISSN: 0301-0430            Impact factor:   0.975


  6 in total

1.  Pharmacokinetics of vancomycin in patients undergoing continuous ambulatory peritoneal dialysis.

Authors:  R D Blevins; C E Halstenson; N G Salem; G R Matzke
Journal:  Antimicrob Agents Chemother       Date:  1984-05       Impact factor: 5.191

2.  Vancomycin pharmacokinetics in patients with peritonitis on peritoneal dialysis.

Authors:  B E Magera; J C Arroyo; S J Rosansky; B Postic
Journal:  Antimicrob Agents Chemother       Date:  1983-05       Impact factor: 5.191

Review 3.  Clinical pharmacokinetics of vancomycin.

Authors:  G R Matzke; G G Zhanel; D R Guay
Journal:  Clin Pharmacokinet       Date:  1986 Jul-Aug       Impact factor: 6.447

4.  Effect of vancomycin hydrochloride on Staphylococcus epidermidis biofilm associated with silicone elastomer.

Authors:  R C Evans; C J Holmes
Journal:  Antimicrob Agents Chemother       Date:  1987-06       Impact factor: 5.191

5.  Comparative study of intraperitoneal and intravenous vancomycin pharmacokinetics during continuous ambulatory peritoneal dialysis.

Authors:  G D Morse; D F Farolino; M A Apicella; J J Walshe
Journal:  Antimicrob Agents Chemother       Date:  1987-02       Impact factor: 5.191

6.  [Treatment of peritonitis during continuous ambulatory peritoneal dialysis (CAPD) with co-trimoxazole, cefazolin or vancomycin].

Authors:  U König; U Müller; U Binswanger
Journal:  Klin Wochenschr       Date:  1987-07-15
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.